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Abstract 
Background: Diabetic retinopathy is the most common complication in diabetic patients relates to high expression 
of VEGF and microaneurysms. Scutellarin (Scu) turned out to be effective against diabetes related vascular endothe‑
lial cell dysfunction. However, its clinical applications have been limited by its low bioavailability. In this study, we 
formulated and characterized a novel intestinal target nanoparticle carrier based on amphiphilic chitosan deriva‑
tives (Chit‑DC‑VB12) loaded with scutellarin to enhance its bioavailability and then evaluated its therapeutic effect in 
experimental diabetic retinopathy model.
Results: Chit‑DC‑VB12 nanoparticles showed low toxicity toward the human colon adenocarcinoma (Caco‑2) cells 
and zebra fish within concentration of 250 μg/ml, owing to good biocompatibility of chitosan. The scutellarin‑loaded 
Chit‑DC‑VB12 nanoparticles (Chit‑DC‑VB12‑Scu) were then prepared by self‑assembly in aqueous solution. Scan‑
ning electron microscopy and dynamic light scattering analysis indicated that the Chit‑DC‑VB12‑Scu nanoparticles 
were spherical particles in the sizes ranging from 150 to 250 nm. The Chit‑DC‑VB12‑Scu nanoparticles exhibited high 
permeation in Caco‑2 cell, indicated it could be beneficial to be absorbed in humans. We also found that Chit‑DC‑
VB12 nanoparticles had a high cellular uptake. Bioavailability studies were performed in Sprague–Dawley rats, which 
present the area under the curve of scutellarin of Chit‑DC‑VB12‑Scu was two to threefolds greater than that of free 
scutellarin alone. Further to assess the therapeutic efficacy of diabetic retinopathy, we showed Chit‑DC‑VB12‑Scu 
down‑regulated central retinal artery resistivity index and the expression of angiogenesis proteins (VEGF, VEGFR2, and 
vWF) of retinas in type II diabetic rats.
Conclusions: Chit‑DC‑VB12 nanoparticles loaded with scutellarin have better bioavailability and cellular uptake 
efficiency than Scu, while Chit‑DC‑VB12‑Scu nanoparticles alleviated the structural disorder of intraretinal neoves‑
sels in the retina induced by diabetes, and it also inhibited the retinal neovascularization via down‑regulated the 
expression of angiogenesis proteins. In conclusion, the Chit‑DC‑VB12 nanoparticles enhanced scutellarin oral delivery 
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Background
Diabetic retinopathy (DR) is a major cause of blindness 
in young adults [1, 2], related to high expression of VEGF 
and microaneurysms [3, 4]. Current treatment modali-
ties, including laser photocoagulation and intraocular 
injection of VEGF antagonists, are invasive and may 
carry detrimental side effects. The negative outcomes 
of current treatments could be prevented by using oral 
administration [3].
Scutellarin (4′,5,6-trihydroxyflavone-7-O-glucuronide, 
Scu, Fig.  1a) [5], is the primary active ingredient of the 
traditional Chinese herb Erigeron breviscapus (Vant.) 
Hand. Mazz [6, 7], which has been extensively used to 
treat vascular endothelial cell dysfunction by many path-
ways of action [8–11]. Based on experimental study and 
clinical observation, scutellarin exerts a potent effect 
against neovascularization and increases vascular perme-
ability by reducing blood viscosity, dilating micro-blood 
vessels and improving microcirculation [12, 13]. Gao 
et  al. [14] reported that high glucose or hypoxia could 
induce expression of VEGF and proliferation of human 
retinal endothelial cells. Furthermore, he also showed 
that scutellarin could significantly inhibit VEGF expres-
sion and the proliferation of human retinal endothelial 
cells. However, low oral bioavailability and low water 
solubility (0.16  mg/ml) [15] of scutellarin limited its’ 
therapeutic application [16]. In this regard, Xiao et  al. 
[17] increased the Papp(AP-BL) of scutellarin by 3.5 fold by 
using membranes over expressing several common trans-
porters, which enhanced the transportation of scutellarin 
and improved the oral absorption of scutellarin.
Followed the rapid development of nanotechnolo-
gies, chitosan played an important role in the biological 
fields [18–21]. We have prepared triamcinolone aceton-
ide acetate-loaded deoxycholic acid-modified chitosan 
nanoparticles (TAA/DA-Chit), which increased the 
efficacy and exhibited potential as small intestinal target promising nano‑carriers for treatment of type II diabetes 
induced‑retinopathy.
Keywords: Chitosan, Diabetic retinopathy, Human colon adenocarcinoma cells, Nanoparticle, Scutellarin, Vascular 
endothelial growth factor
Fig. 1 Chemical structures of a scutellarin and b the Chit‑DC‑VB12 derivative, c self‑assembly mechanism of the Chit‑DC‑VB12 derivative and 
scutellarin in aqueous solution
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water solubility of triamcinolone acetonide acetate from 
0.3 to 2.1 mg/ml, and decreased VEGF mRNA expression 
in human retinal pigment epithelial cells [22]. Recent 
studies demonstrated that chitosan and its derivatives 
based nanoparticles could open the tight junction con-
necting enterocytes in the small intestine, and possess a 
high affinity with the negatively charge mucin that forms 
the mucus matrix, resulting in improving oral-admin-
istrated drug absorption [23–25]. In addition, vitamin 
B12 (VB12) is considered as a hopeful agent to enhance 
utilization of oral drug delivery [26], because VB12 can 
be transported through the small intestine by receptor-
mediated endocytosis [25, 27]. Following oral adminis-
tration, VB12 binds to intrinsic factor (IF) to constitute 
a complex. Upon reaching the small intestine, this com-
plex binds to IF receptors located in the luminal surface 
of the intestine, facilitating the transport across intestinal 
epithelium by receptor-mediated endocytosis. In previ-
ous works [28], after modified by VB12, nanoparticles 
showed significantly higher drug internalization in cell 
model than unmodified nanoparticles, and an increased 
transportation of insulin. However, no such report is 
available where this concept has been used for oral deliv-
ery of scutellarin.
Therefore, in this study, in order to prepare the nano-
particles to improve the water-solubility and bioavail-
ability of scutellarin, the amphiphilic chitosan derivatives 
(Chit-DC) were synthesized based on our previous work 
[22]. And then VB12, as a small intestinal targeting fac-
tor, was conjugated with the Chit-DC derivative to 
yield the amphiphilic chitosan derivatives containing 
vitamin B12 (Chit-DC-VB12, Fig.  1b) using the mild 
N,N′-carbonyldiimidazole (CDI) activation method 
[29]. Structures of Chit-DC and Chit-DC-VB12 were 
characterized by FTIR and 1H NMR spectroscopy. The 
scutellarin-loaded Chit-DC-VB12 (Chit-DC-VB12-Scu) 
nanoparticles were prepared in aqueous solutions and 
optimized to the experimental conditions in order to 
maximize the payload of scutellarin and its bioavailabil-
ity (Fig.  1c). In this study, we evaluated the release and 
pharmacodynamics of scutellarin via complexation with 
amphiphilic chitosan derivatives Chit-DC and Chit-DC-
VB12, which were developed in our previous study, and 
our results indicated that the amphiphilic chitosan deriv-
atives and VB12 labeled process were able to increase the 
bioavailability and targeted release of scutellarin.
Methods
Materials
Scutellarin (purity 98%) was purchased from Jiexiang 
Pharmaceutical Industry Ltd. (Sichuan, China). Chi-
tosan (deacetylation degree of 90% and average molecu-
lar weight of 450  kDa) was purchased from Shanghai 
Bo’ao Biological Technology Co, Ltd (Shanghai, China). 
Deoxycholic acid was purchased from Acros Organics 
Corp (Antwerp, Belgium). N-(3-dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride (EDC) was obtained 
from Shanghai Medpep Co, Ltd (Shanghai, China, AR). 
FITC was sourced from Sigma-Aldrich (St Louis, MO). 
Vitamin B12 was purchased from Sigma (St Louis, USA). 
CDI and dimethyl sulfoxide (DMSO) were acquired from 
Aladdin Reagent Company (Shanghai, China). Cell count-
ing kit-8 (CCK-8) was purchased from Dojindo Molecu-
lar Technologies Inc, (Kumamoto, Japan). Zebra fish 
embryos were kindly provided by the Zebra fish Model 
Animal Facility at the Institute of Clinical and Transla-
tional Research of Sun Yat-sen University. Primary anti-
bodies against VEGF, VEGFR2, vWF and Horseradish 
peroxidase (HRP)-conjugated secondary antibodies were 
obtained from Cell Signaling Technology (Beverly, MA).
Synthesis of Chit‑DC, Chit‑DC‑VB12 derivatives, 
FITC‑labeled Chit‑DC and Chit‑DC‑VB12 derivatives
The Chit-DC derivative was synthesized based on our 
previous work [22]. In brief, chitosan (1.0  g, 6.21  mmol 
of glucosamine unit) was dissolved in 90 ml of 1% aque-
ous acetic acid/ethanol (4/5, v/v) in the reactor, fol-
lowed by adding with 15 ml of Deoxycholic acid (0.85 g, 
2.17  mmol) and EDC (0.62  g, 3.26  mmol) dissolved 
ethanol solution, and the mixture was reacted at room 
temperature for 24 h. The reacted mixture was then neu-
tralized by the dropwise addition of ethanol/ammonia 
solution (7/3, v/v), precipitated with 300  ml of ethanol, 
and then centrifuged (3500  rpm, 10  min). The result-
ant precipitate was dissolved in distilled water, dia-
lyzed against distilled water for 3  days, and lyophilized 
to yield the Chit-DC derivative. Vitamin B12 (0.171  g, 
0.124 mmol) was dissolved in 5 ml of anhydrous DMSO, 
activated by adding CDI (23 mg, 0.142 mmol), and then 
stirred for 1  h in a nitrogen atmosphere at room tem-
perature. The Chit-DC derivative (0.04  g, 0.248  mmol 
amino-glucose units) was dissolved in 20 ml of anhydrous 
DMSO, and was added to the vitamin B12 reaction solu-
tion, and the mixture was reacted for 24 h in a nitrogen 
atmosphere at room temperature. The mixture was finally 
dialyzed against distilled water for 3 days, and lyophilized 
to yield the solid products of Chit-DC-VB12. The Chit-
DC derivative (10 mg, 0.062 mmol amino-glucose units) 
was dissolved in 10 ml of PBS solution (pH = 6.2). FITC 
(1 mg, 0.0025 mmol) was dissolved in 0.8 ml of DMSO, 
and then added to the Chit-DC derivative solution. The 
mixture was reacted for 4 h in the dark at room tempera-
ture before dialyzed against distilled water for 3 days and 
lyophilized to yield Chit-DC-FITC. The FITC-labeled 
Chit-DC-VB12 (named as Chit-DC-VB12-FITC) deriva-
tive was synthesized using the same method.
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Preparation and properties of scutellarin‑loaded 
nanoparticles
Scutellarin is soluble in methanol and PBS solution 
(pH7.2), but poorly dissolved in the distilled water. 
Herein, the scutellarin-loaded nanoparticles were pre-
pared in the mixture solvent of the distilled water and 
methanol as follows. Chit-DC (10  mg) was soaked in 
3 ml of distilled water, gently shaken for about 2 h, and 
then a solution containing 3.5 mg of scutellarin in 0.5 ml 
methanol was added with stirring. Next, 1  ml of dis-
tilled water was slowly added dropwise and the mixture 
was stirred for 24  h. After methanol was evaporated by 
heating at 40  °C, the resultant solution was centrifuged 
at 5000  rpm for 5  min, yielding supernatant containing 
Chit-DC-Scu nanoparticles. Unloaded scutellarin in the 
precipitate was dissolved in PBS solution (pH7.2), and its 
concentration was analyzed by UV–Vis spectrophotom-
etry as mentioned above at 330 nm. Standard scutellarin 
solutions were prepared at concentrations ranging from 
5 to 50 μg/ml in PBS (pH7.2) solution, and the correla-
tion coefficient value (R2) was at least 0.999. The loading 
capacity was calculated using Eq. (1).
where A is the total weight of scutellarin used, B is the 
weight of unloaded scutellarin in the precipitate after 
centrifugation, and C is the weight of Chit-DC. The Chit-
DC-VB12-Scu nanoparticles were measured using the 
same method.
Structural characterization and physicochemical property
The molecular structures of different samples were 
performed with a FTIR Analyzer (Nicolet/Nexus 670, 
Thermo Nicolet Corporation, Wisconsin, USA) at a reso-
lution of 4 cm−1 using the KBr pellet method. The chemi-
cal structures of different samples were analyzed using 
1H NMR spectroscopy. The degree of substitution of the 
vitamin B12 residues in the VB12 grafting samples were 
determined by UV–Vis spectrophotometry (PE-Lambda 
750, PerkinElmer, Waltham, MA) and a standard curve 
of vitamin B12 in DMSO (concentration: 5–50  μg/ml, 
λ = 360 nm, R2 = 0.999). Fluorescence measurements of 
FITC-labeled derivatives were carried out on a spectro-
fluorophotometer (RF-5301PC, Shimadzu Corporation, 
Japan) with a maximum excitation wavelength of 470 nm 
over a scanning wavelength range of 550–750  nm, and 
excitation and emission slits of 5  nm. Morphology of 
Chit-DC-VB12-Scu nanoparticles was observed on an 
S-4800 scanning electron microscope (HI-9056-0003, 
Hitachi, Japan). Hydrodynamic diameter distribution 
of Chit-DC-VB12-Scu nanoparticles was estimated by 
dynamic light scattering experiment on a dynamic/static 
(1)Loading capacity (%) = ((A− B)/C)× 100
laser scattering system (BI-200SM, Brookhaven Instru-
ments Corporation, New York, USA) at 25 °C.
Cell culture
Caco-2 cells were obtained from the American type cul-
ture collection (ATCC, Manassas, VA). Cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (Invitro-
gen) and antibiotics (100  U/ml penicillin and 100  U/ml 
streptomycin) in a humidified incubator at 37  °C in 5% 
CO2. Caco-2 cells from passage 30–50 were used in the 
experiments. The cells were seeded on 96-well tissue cul-
ture plates (Corning-Costar) for cell toxicity assays and 
12-Transwell tissue culture plates for cell transmembrane 
assays.
Cytotoxicity assay
CCK-8 allows sensitive colorimetric assays for the deter-
mination of the number of viable cells in cell prolifera-
tion and cytotoxicity assays. Caco-2 cells were seeded 
in 96-well plates (3000–5000 cells/well) for each respec-
tive compound. Following overnight incubation and 
replacement with fresh medium, the cells were then incu-
bated for another 48  h with Chit-DC or Chit-DC-VB12 
in the range of 6–250  μg/ml. 10  μl of CCK-8 solution 
(Dojindo Molecular Technologies Inc, Japan) was added 
to each vial and plates were incubated for 2 more hours 
at 37  °C in a humidified CO2 incubator [30]. Absorb-
ance at 450 nm was monitored with a microplate reader 
(Thermo, USA) and the relative cell viability was calcu-
lated from the means of triplicates. Cell survival rate is 
expressed as percentage of control.
Zebra fish embryo assay
Fertilized eggs were transferred into 96-well plates (1 
egg per well), and different concentrations Chit-DC and 
Chit-DC-VB12 were added into the zebra fish embryo 
medium in the range of 6–250 μg/ml. The development 
of the zebra fish embryos was evaluated using the micro-
scope at the moment of nanoparticle addition and then 
longitudinally monitored at 24, 48, 72 and 96 h of post-
fertilization (hpf) to assess toxicity and potential devel-
opmental defects [31–33].
Pharmacokinetics study in vivo
Male Sprague–Dawley rats (weighing 220–250  g) were 
fasted for 12  h, but allowed water ad  libitum the day 
before drug administration. Scutellarin, Chit-DC-Scu, 
and Chit-DC-VB12-Scu were resuspended in PBS and 
administered to rats (at the same scutellarin dose of 
40  mg/kg) by oral gavage. Blood samples (0.2  ml) were 
collected from the tail vein of each rat before dosing and 
at 0.25, 0.5, 0.75, 1, 2, 3, 5, 8, 12, 24  h post-dosing. An 
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equal volume of 0.9% saline solution was injected after 
each collection. Plasma samples were obtained by cen-
trifugation at 10,000  rpm for 10  min immediately after 
blood collection and were stored at −20  °C until analy-
sis [7]. HPLC (Agilent 1100, USA) was used to determine 
the concentration of scutellarin in plasma [7, 34].
Caco‑2 cell permeability of scutellarin, Chit‑DC‑Scu 
and Chit‑DC‑VB12‑Scu
Caco-2 cells were seeded in 12-well transport inserts at a 
density of 2 × 105 cells/cm2 in DMEM. Cells were main-
tained at 37  °C in a humidified atmosphere containing 
5% CO2 for 21  days. Monolayers with transendothelial 
electrical resistance values above 300  Ω  cm2 were used 
in this study. On the day of the transport experiments, 
the culture medium was replaced with hank’s balanced 
salt solution (HBSS). Before the assay, Caco-2 cells mon-
olayers was rinsed twice and incubated with the trans-
port medium for an hour. After removing the transport 
medium, scutellarin, Chit-DC-Scu, Chit-DC-VB12-Scu 
(10 μg/ml scutellarin) alone or in the presence of IF (Inter-
nal factor, 20 μl of a 100 IU/ml solution) were add to the 
apical side (0.5 ml) and 1.5 ml DMEM was added to the 
basolateral side of Transwell inserts. Cells were maintained 
at 37  °C in a humidified atmosphere containing 5% CO2 
with orbital shaking at 50  rpm throughout the assay. At 
pre-determined intervals of 0, 30, 60, 90 and 120 min, 50 μl 
of transport buffer at the basolateral side was collected and 
mixed with the same volume of methanol, and an equal 
amount of DMEM was instantly added to the basolateral 
side to maintain a constant dissolution volume. The assay 
was performed in triplicate. Concentrations of scutellarin, 
Chit-DC-Scu and Chit-DC-VB12-Scu in corresponding 
samples were assessed by HPLC [35, 36].
Cellular uptake efficiency of FITC‑labeled Chit‑DC 
nanoparticles
Scutellarin does not carry fluorescence, which is not 
conducive to the direct observation of cellular uptake 
efficiency of scutellarin-loaded nanoparticles. There-
fore, cellular uptake efficiency of nanoparticles was 
investigated using FITC labeled nanoparticles instead of 
scutellarin-loaded nanoparticles, similar to our previous 
experiments [22]. To study their uptake in Caco-2 cells, 
Chit-DC-FITC, Chit-DC-VB12-FITC alone or in the 
presence of IF (20 μl of a 100 IU/ml solutions) were pre-
pared. Here, Caco-2 cells were seeded in 6-well plates at 
a density of 2.0 ×  105  cells/well in 2  ml of DMEM and 
cultured at 37  °C for 24 h. After replacement with fresh 
media, a solution of Chit-DC-FITC and Chit-DC-VB12-
FITC nanoparticles (1.0 mg/ml) in the absence of IF was 
then added to each well, followed by incubation for 0, 0.5, 
1 and 2 h. Next, the cells were washed three times with 
3 ml of phosphate-buffered solution (pH 7.4) and fluores-
cent images were made by fluorescence microscopy [22]. 
All images were analyzed by Image ProPlus 6.0 software.
Animals and type 2 diabetic model
Type 2 diabetes was induced in male Sprague–Dawley 
rats (weighing 230–250  g, Experimental Animal Center 
of Sun Yat-sen University, China. Certificate No: SCXK 
(Q) 2011-0029). All animals were housed five per cage 
in a room and maintained at a constant temperature 
(22  °C) under a 12/12 h light/dark cycle. All procedures 
were carried out according to the National Institutes 
of Health Guide for Care and Use of Laboratory Ani-
mals and were approved by the Bioethics Committee of 
Sun Yat-sen University. Rats were randomly assigned to 
a control group, a Scu group (normal rats with 40  mg/
kg/day scutellarin treatments), and five type II diabetes 
model groups (n = 8/group). The control and Scu groups 
were fed for 16  weeks on regular standard diets, while 
rats from type II diabetes model groups (T2D) were fed 
a high-fat (HFS, Guangdong Medical Laboratory Ani-
mal Center, Guangzhou, China) diet for 16  weeks that 
consisted of 30% from total kcal from fats, 55% from car-
bohydrates and 15% from protein. After 8 weeks on the 
HFS diet, rats in the T2D groups were fasted overnight 
and each rat received a single intraperitoneal injection of 
streptozotocin (STZ, Sigma, USA) at a dose of 30 mg/kg 
body weight the following morning while the rats in the 
control group were injected with an equal volume of cit-
rate buffer. The STZ was freshly diluted in citrate buffer 
(0.1 mol/l, pH 4.0). After the injection, the HFS diet feed-
ing was continued [37]. Blood glucose and body weight 
were monitored 3  days after the STZ or citrate buffer 
injection, and once a week thereafter. Induction of the 
diabetic state was confirmed by measuring the tail blood 
glucose (BG) level 7 days after STZ injection. Rats with 
blood glucose levels >16.7 mmol/l on at least three occa-
sions were deemed to be diabetic [38]. After 1  week of 
the STZ injections, rats from T2D groups were randomly 
divided into five groups: DM group, DM  +  Scu group, 
DM  +  Chit-DC group, DM  +  Chit-DC-Scu group and 
DM  +  Chit-DC-VB12-Scu group. These rats received 
intragastrically administered phosphate buffer (0.1 M, pH 
7.4), scutellarin, Chit-DC, Chit-DC-Scu, Chit-DC-VB12-
Scu (scutellarin-loaded nanoparticles at the same scutel-
larin does for 40 mg/kg/day) for 8 weeks. The equivalent 
volume of phosphate buffer was used as vehicle control 
for the control group. At the 16th week, all rats were 
anesthetized and sacrificed.
Color Doppler sonography analysis
Prior to sacrifice, all rats were anesthetized and color 
Doppler sonography analysis of the right eye was 
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performed. The central retinal vasculature was local-
ized with a MS 400 probe (18–38  MHz) color Doppler 
sonography (VisualSonics Vevo 2100, Toronto, Canada) 
[39]. Color images were shown in real time and Doppler 
spectral analyses were done. At least three measurements 
were recorded for each animal and the mean of the three 
readings was taken as the representative value. The resis-
tivity index (RI) of the central retinal artery (CRA) was 
calculated by subtracting the diastolic velocity (DV) from 
the peak systolic velocity (SV) and then dividing by the 
systolic velocity [(SV − DV)/SV] [40].
Immunohistochemistry
For histopathological analysis, rats were sacrificed and 
their eyes were immediately enucleated and cut verti-
cally through the center of the cornea and optic nerve. 
After 24 h immersion in 4% formaldehyde in 0.1 M phos-
phate buffer (pH7.2) and dehydration in a graded ethanol 
series, eyes were embedded in paraffin. Eyes were sliced 
into 5  μm-thick sections. After being deparaffinized, 
hematoxylin and eosin-stained slides were prepared by 
using the standard method [41].
Western blot analysis
From the retinal homogenates, 30–40 μg of the extracted 
proteins were fractionated on SDS-PAGE, and then trans-
ferred to PVDF membranes (Millipore, USA). GAPDH 
was used to normalize the total tissue lysate on the same 
membrane. Blots were blocked with 5% non-fat dried 
milk for 1 h and then incubated overnight at 4 °C with the 
corresponding primary antibody. Antibodies for VEGF, 
VEGF receptor 2, vWF were used at the 1:500 dilutions. 
Antibodies for GAPDH were purchased from Kangcheng 
Inc. (Shanghai, China) and used at 1:5000 dilutions. After 
three washes, membranes were incubated with horserad-
ish peroxidase conjugated goat anti-rabbit IgG antibody 
(1:1000) for 1 h at room temperature. Then protein was 
visualized with Immobilon Western Chemiluminescent 
HRP Substrate (Millipore, USA).
Statistical analysis
Data are presented as mean ± SD of experiments. Data 
were analyzed by the computer program SPSS 17.0 (SPSS 
Inc., Chicago, IL, USA) by means of an unpaired two-
tailed Student’s t test. Results were considered statisti-
cally significant at a P value of <0.05.
Results
Synthesis and structural analysis of vitamin B12‑modified 
amphiphilic chitosan derivatives
Based on the synthesis method as illustrated in Fig.  2, 
the Chit-DC derivative was firstly synthesized using 
EDC as a coupling reagent at room temperature and its 
productivity is 86%. When compared with the 1H NMR 
spectrum of deoxycholic acid (Additional file 1a), proton 
signals of the Chit-DC derivative are assigned as follows: 
δ = 2.8–4.2 ppm (H2–H6 protons of chitosan), δ = 0.6–
2.5  ppm (protons of deoxycholic acid residues) (Addi-
tional file  1b). The degree of substitution (DS) of the 
deoxycholic acid residues of the Chit-DC derivative was 
determined to be 3% by the integration method, which is 
defined as the number of deoxycholic acid residues per 
100 amino-glucose unit of chitosan.
Vitamin B12 was then activated by CDI and conjugated 
with the Chit-DC derivative at room temperature to yield 
the Chit-DC-VB12 derivative (the productivity is 67%) 
(Fig. 2). In the 1H NMR spectrum of the Chit-DC-VB12 
derivative (Additional file 1c), the proton signals of H2–
H6 protons of chitosan (2.8–4.2  ppm) and deoxycholic 
acid residues (0.2–2.5 ppm) were also observed. It should 
be noted that the characteristic resonance peaks of VB12 
protons were obviously observed in the 1H NMR spec-
trum of the Chit-DC-VB12 derivative (Additional file 1c, 
peaks labelled with the dashed lines), which were absent 
in the 1H NMR spectrum of the Chit-DC derivative 
(Additional file 1b). These results confirmed that deoxy-
cholic acid residues and vitamin B12 residues were con-
jugated with the chitosan chains. Since the proton signals 
of vitamin B12 residues overlapped with those of deox-
ycholic acid residues, the DS value of the vitamin B12 
residues was determined to be 0.3% using UV–Vis spec-
troscopy. This value is in consistent with the DS value of 
the vitamin B12 residues conjugated with dextran [27].
In order to investigate the cellular uptake efficiency of 
the amphiphilic chitosan derivatives of the CaCo-2 cells, 
fluorescent FITC-labeled amphiphilic chitosan deriva-
tives were synthesized according to Additional file 2 [42, 
43]. In the FTIR spectrum of the Chit-DC-FITC deriva-
tive (Additional file  3A), peaks at 1167 and 885  cm−1 
are assigned to the characteristic vibrations of the C=S 
bond and the benzene skeleton, respectively. These peaks 
are different from the peaks in the FTIR spectrum of the 
Chit-DC derivative (Additional file 3A). This proves that 
the FITC residues were conjugated with the Chit-DC 
chains. The same result was obtained for the Chit-DC-
VB12-FITC derivative.
Additional file  3B shows the fluorescence spectra of the 
Chit-DC-FITC derivative and the Chit-DC-VB12-FITC 
derivative in PBS (pH = 7.2) solution. The derivatives exhib-
ited characteristic fluorescence emission peaks of FITC by 
demonstrating maximum fluorescence peaks at 520 and 
516 nm, respectively. In addition, yellow-green fluorescence 
was observed when these derivatives were illuminated with 
ultraviolet light (λ = 365 nm). These fluorescence properties 
further confirmed the conjugation of FITC residues with 
two the amphiphilic chitosan derivatives.
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Preparation and properties of scutellarin‑loaded 
nanoparticles
In order to improve the absorption efficacy of scutellarin 
by the small intestine after oral administration, scutella-
rin-loaded nanoparticles based on the Chit-DC deriva-
tive and the Chit-DC-VB12 derivatives were prepared. 
Scutellarin was dissolved in a small amount of methanol 
and then was added dropwise to an aqueous solution of 
two chitosan derivatives. After dropwise addition of dis-
tilled water as a selective solvent for the chitosan deriva-
tives and removal of methanol, the scutellarin molecules 
were gradually entrapped into the hydrophobic micro-
domains of the chitosan derivatives via self-assembly 
(Additional file 1C). The scutellarin loading capacities of 
the Chit-DC derivative and the Chit-DC-VB12 derivative 
were determined to be 15 and 13% using UV–Vis spec-
troscopy, respectively.
Figure  3a shows a photo of the Chit-DC-VB12-Scu 
solution, in which the Tyndall phenomenon was observed 
following illumination with a red laser (λ  ≈  670  nm), 
indicating the formation of nanoparticles in the solution. 
Morphology of scutellarin-loaded Chit-DC-VB12 nano-
particles was then investigated by scanning electron 
microscopy analysis. As showed in Fig.  3b, they were 
observed as spherical particles in the sizes ranging from 
150 to 250 nm. Their hydrodynamic diameters were fur-
ther determined to be 182  ±  11  nm by dynamic light 
scattering analysis (Fig.  3c). The zeta potential of Chit-
DC-VB12-Scu nanoparticles is 16.5 ± 3.1 mv.
Cytotoxicity and biocompatibility of Chit‑DC
The cytotoxicity tests for Chit-DC, and Chit-DC-VB12 
were evaluated in Caco-2 cells using the CCK-8 assay. 
The highest concentration of Chit-DC and Chit-DC-
VB12 evaluated was 250  μg/ml. From Fig.  4a, we found 
Chit-DC and Chit-DC-VB12 nanoparticles cause low tox-
icity to the Caco-2 cells up to a concentration of 250 μg/
ml, with cell viability is 85.09 ± 3.29% and 85.02 ± 4.34% 
respectively.
Zebra fish, as a vivo animal model, is considered as a 
more definitive assessment of toxicity, and it can clearly 
show the embryo toxicity [32, 33]. Thus, we used zebra 
Fig. 2 Synthesis of the Chit‑DC‑VB12 derivative
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fish embryo to assess acute toxic effects and long term 
developmental defects resulting from exposure to Chit-
DC and Chit-DC-VB12. As showed in Fig. 4b, we can see 
the normal morphology of Zebra fish embryo develop-
ment in different times under standard/healthy condi-
tions. At 72 h after adding Chit-DC or Chit-DC-VB12 to 
the embryos, embryo development cannot be affected at 
the concentration of 250 μg/ml (Fig. 4c).
Pharmacokinetics study in vivo
Pharmacokinetics study on the Chit-DC-Scu and Chit-
DC-VB12-Scu was performed in rats via a single oral 
administration at a dose of 40 mg/kg (scutellarin-loaded 
nanoparticles at the same scutellarin dose for 40  mg/
kg). Figure 5 demonstrated the profiles of the scutellarin 
blood concentration versus time in the plasma. The total 
plasma concentrations of the scutellarin in Chit-DC-Scu 
and Chit-DC-VB12-Scu were significantly higher than 
free scutellarin alone (Table  1). In particular, the area 
under the curve (AUC) of scutellarin from the conjugated 
compounds was about two to threefold greater than that 
from the free scutellarin alone, indicating that Chit-DC-
Scu and Chit-DC-VB12-Scu had better bioavailability 
compared to scutellarin. The elimination half-life (T1/2β) 
in the Chit-DC-Scu and Chit-DC-VB12-Scu group was 
2.434 ± 0.154 h and 2.720 ± 0.250 h, respectively. Com-
pared to the scutellarin group, the respective signals were 
29.12 and 44.31% longer.
Permeability and cellular uptake in Caco‑2 cell monolayers
In the present study, in order to further determine the 
possibility of transcellular transport of nanoparticles 
across a monolayer, the intracellular uptake of scutel-
larin was assessed in  vitro using Caco-2 cell monolay-
ers (Fig.  6a). The transport of scutellarin from the AP 
side to the BL side in the Caco-2 cell model was mod-
erate with a Papp value of 3.2  ×  10−7  cm/s. Chit-DC-
Scu, with a Papp value of 9.07  ×  10−7  cm/s. We also 
observed a significant enhancement in the amount of 
transported scutellarin after incorporation within VB12-
conjugated micelles (14.05  ×  10−7  cm/s), compared 
to the amount of scutellarin transported by Chit-DC. 
Based on the previous research [44], only about 1% of 
scutellarin was absorbed by the small intestine for the 
scutellarin group, more scutellarin was absorbed for the 
Chit-DC-Scu group. Moreover, the absorption rate can 
Fig. 3 Photo of the Chit‑DC‑VB12‑Scu solution (a) and scanning electron microscopy image of Chit‑DC‑VB12‑Scu nanoparticles (b) and hydrody‑
namic diameter distribution of Chit‑DC‑VB12‑Scu nanoparticles (c)
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be improved significantly after scutellarin was loaded 
by Chit-DC-VB12. In addition, Papp value increased 
to 17.21  ×  10−6  cm/s, suggesting that the transcyto-
sis is even more efficient when extrinsic IF is added to 
the medium. After 2  h of incubation, the Papp value of 
Chit-DC-Scu and Chit-DC-VB12-Scu was threefold and 
fivefold higher respectively, than Papp of the free scutel-
larin (Fig. 6a; p < 0.05), the addition of extrinsic IF to the 
medium also increased the Papp values to sixfold higher 
than that of the free scutellarin. Finally, the addition of 
the drug, nanoparticles, and IF to the AP side of Caco-2 
monolayers did not affect TEER values significantly, sug-
gesting that the integrity of the monolayers was main-
tained throughout the permeability experiment.
Fluorescence microscopy was used to further confirm 
the cellular uptake efficiency of nanoparticles. Nanopar-
ticles loaded with a green fluorescence label (FITC). In 
previous experiments, we have prepared TAA/DA-Chit, 
Fig. 4 Cytotoxicity and biological toxicity induced by Chit‑DC and Chit‑DC‑VB12. a CCK‑8 cytotoxicity assay was performed in Caco‑2 cells. 
The results are shown as the mean ± SD for three independent trials. b Zebra fish embryo development under standard/healthy conditions 
(hpf = hours post‑fertilization). c Zebra fish embryo development after 24, 48, 72, 96 hpf of incubation with different concentrations of Chit‑DC and 
Chit‑DC‑VB12
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and its cellular uptake efficiency was investigated using 
FITC/DA-Chit nanoparticles instead of TAA/DA-Chit 
nanoparticles [22]. In this experiment, Chit-DC-FITC 
instead of Chit-DC-Scu nanoparticles was used in the 
study. Fluorescent images of the ARPE-19 cells showed 
that green fluorescent density in the cells increased and 
spread throughout the cells as incubation time increased 
(Fig.  6b, c). As showed in Fig.  6, VB12 functionalized 
nanoparticles were taken up by Caco-2 cells to a greater 
extent than Chit-DC alone, and this enhancement in 
uptake was further improved in the presence of IF 
(Fig. 6b, c). These results indicate that FITC was delivered 
effectively into cells by the Chit-DC-FITC nanoparticles.
Animals and type 2 diabetic model
When compared to the control group, we observed that 
the mean blood glucose level was elevated significantly 
in T2D group, and there were no significant changes in 
blood glucose levels between five T2D groups (Addi-
tional file  4A). All rats in the T2D group maintained 
high blood glucose until the end of 16 weeks. The mean 
body weight of the Control and Scu group was gradual 
increased, while that of the T2D group was decreased 
after 8th week (Additional file 4B). However, the rats in 
the DM +  Chit-DC-Scu and DM +  Chit-DC-VB12-Scu 
groups showed slow declines in body weight compared 
with the DM, DM + Chit-DC and DM + Scu group.
Blood flow alteration and retinal pathology
No significant changes in blood flow velocity or RI in 
the control and Scu rats were observed. The blood flow 
velocity in T2D rats was significantly lower than that in 
non-diabetic rats, and the resistivity indexes (RIs) as 
calculated from Doppler measurement [45] were sig-
nificantly elevated in T2D rats (Fig. 7). Chit-DC-Scu and 
Chit-DC-VB12-Scu significantly reduced the retinal RI 
value and increased the blood flow velocity in T2D rats 
compared to DM rats, but the retinal RI value was still 
higher than non-diabetic animals. When compared to 
T2D rats or T2D rats treated with Chit-DC, Scu therapy 
reduced retinal RI values and increased blood flow veloc-
ities (Fig.  7b). When compared to groups administered 
Chit-DC-Scu and Chit-DC-VB12-Scu, treatment with 
scutellarin alone failed to achieve the same therapeutic 
effect (Fig. 7c).
Retinal pathology was detected by hematoxylin and 
eosin staining, and we investigated retinal morphology 
(Fig.  7d). We observed that retinal cell layers of con-
trol and Scu group were continuous with normal capil-
lary structure, but the arrangement of ganglion cells and 
inner nuclear layer cells was disorder in the T2D rat’s 
retina. After treatment with Chit-DC-Scu and Chit-DC-
VB12-Scu, the structural disorder of intraretinal arrange-
ment in the retina was eased.
Western blot analysis
According to previous reports, VEGF is a major patho-
genic factor and effective therapeutic target for DR, 
VEGF receptor 2 (VEGFR2) is the receptor responsible 
for transducing VEGF induced signaling [46], and vWF 
is an indicator of measuring angiogenesis [47]. Thus, we 
assessed the expression of VEGF, VEGR2 and vWF in 
the retina of rats treated with scutellarin-loaded nano-
particles by western blot assay. As illustrated in Fig.  8, 
the expression of VEGF, VEGFR2 and vWF in diabetic 
rats treated with scutellarin, Chit-DC-Scu or Chit-DC-
VB12-Scu is downregulated compared to that of diabetic 
Fig. 5 Pharmacokinetics study in vivo. Plasma concentration–time 
curve of scutellarin after a single oral dose of Scutellarin, Chit‑DC‑Scu, 
or Chit‑DC‑VB12‑Scu (at the same scutellarin dose of 40 mg/kg) in 
rats (n = 6)
Table 1 Pharmacokinetic parameters and bioavailability of oral formulations
Each data point represents mean ± SD, n = 6 for plasma pharmacokinetic parameters
AUC is for scutellarin in plasma
* Significantly different (P < 0.05) from Scu group
T1/2(α) (h) T1/2(β) (h) Tmax (h) Cmax (ng/ml) AUC(0−∞) (ng h/ml)
Scu 0.405 ± 0.055 1.885 ± 0.105 1.235 ± 0.025 128.533 ± 85.467 6.419 ± 1.051
Chit‑DC‑Scu 1.446 ± 0.136 2.434 ± 0.154 2.375 ± 0.095 196.653 ± 45.239* 13.034 ± 1.135*
Chit‑DC‑VB12‑Scu 2.529 ± 0.064 2.720 ± 0.250 3.776 ± 0.198 213.666 ± 81.786* 22.096 ± 2.064*
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rats treated with or without Chit-DC. Additionally, the 
expression of VEGF, VEGFR2 and vWF in diabetic rats 
was higher than that of normal control rats and scutel-
larin treated rats.
Discussion
In spite of the continuous use of drugs such as insulin, DR 
remains the most prevalent cause of blindness in many 
countries. Like other diabetic complications, the exact 
Fig. 6 Permeability and cellular uptake study. a Papp of different scutellarin formulations: Scu, Chit‑DC‑Scu, Chit‑DC‑VB12‑Scu and Chit‑DC‑VB12‑
Scu with IF. (n = 3; data shown is mean ± SD, *p < 0.05 in comparison with Scu group). b Typical fluorescence images of Caco‑2 cells incubated 
with Chit‑DC‑FITC, Chit‑DC‑VB12‑FITC, Chit‑DC‑VB12‑FITC + IF for 0.5, 1 or 2. c The intensities analysis of FITC/DAPI fluorescence ratio of samples 
from 5 independent individuals was used for quantification. The graph shows the mean ± SD of the fluorescence intensities analysis of FITC (green) 
versus DAPI (blue) of samples. *p < 0.05 in comparison with Chit‑DC‑FITC group
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mechanism underlying the formation and process of DR 
is still poorly understood. It is well recognized that DR is 
an ischemic disorder that leads to expressions of multiple 
signal molecules, development of neovascularization, and 
various lesions of the retina. VEGF, one of the important 
protein molecules responsible for the neovascularization 
Fig. 7 The effect of Scu, Chit‑DC‑Scu and Chit‑DC‑VB12‑Scu on blood flow rate and pathological structure of the diabetic retina. a Color Doppler 
sonography analysis was performed in the retina of experimental rats. Quantitative evaluation of retinal blood flow velocity (b) and RI (c) of rats in 
each group. d The pathological changes in the retina of rats observed under the microscope with Hematoxylin–eosin staining (×200). The arrange‑
ment of ganglion cells and inner nuclear layer cells was disorder in T2D rats groups (indicated by the black arrow). *Significantly different from 
control group (P < 0.05); #significantly different from DM group (P < 0.05)
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[48], is produced in response to ischemic hypoxia in 
the retinas of diabetic animals and humans. Following 
release of VEGF and other angiogenic factors, vascular 
endothelial tight junctions loosen, retinal microvascu-
lar endothelial cells and blood vessels walls damaged, 
platelets aggregated and blood flow altered, leading to 
increased vascular permeability and leakage. The pro-
motion of angiogenesis further results in impairment 
of visual function, and eventually leads to microcircu-
lation disturbance. Since VEGF plays a key role in the 
retinal microvascular dysfunction, it represents a valu-
able target for therapeutic intervention in DR. It is well 
established that VEGF and its receptors are important 
mediators during different steps of angiogenesis. While 
VEGF is mediated by many receptor tyrosine kinases, of 
which, VEGFR2 regulates vascular endothelial prolifera-
tion, migration, differentiation, capillary like formation, 
and vascular permeability [49]. Therefore, inhibition of 
the VEGFR2-mediated signaling pathway represents an 
excellent approach to antiangiogenic intervention. Our 
findings illustrated that the expression of VEGF, VEGFR2 
and vWF in diabetic rats was increased, which was abro-
gated by scutellarin, Chit-DC-Scu or Chit-DC-VB12-Scu. 
The activation of VEGFR2 leads to the downstream acti-
vation of several proteins in the mitogen-activated pro-
tein kinases (MAPK) pathway and PI3K-Akt pathway, 
such as p42/44 ERK, JNK, PI3K and Akt [49, 50]. Here, 
we have shown that scutellarin successfully inhibited 
VEGF and VEGFR2 expression in diabetic rats, while the 
effect of scutellarin on these signaling pathways warrants 
further investigation.
At present, few measures are available to prevent DR 
beyond maintenance of glycaemic control, blood pres-
sure control and correction of dyslipidaemia [51, 52]. 
Fig. 8 Effect of scutellarin and scutellarin‑loaded nanoparticles on the expression of VEGF, VEGFR2 and vWF. a Western blot analysis was used to 
determine the expression of VEGF,VEGFR2 and vWF in the rat retina. Quantitative evaluation of protein expression of VEGF/GAPDH (b), VEGFR2/
GAPDH (c) and vWF/GAPDH (d). Data are presented as mean ± SD. *Significantly different from control group (P < 0.05); #significantly different from 
DM group (P < 0.05)
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Beyond control of systemic factors, laser photocoagula-
tion and intravitreal anti-VEGF drugs are the main treat-
ments for DR [3]. However, these therapies are invasive 
and may carry detrimental side effects. Scutellarin is the 
primary active ingredient of the traditional Chinese herb 
Erigeron breviscapus (Vant.) Hand. Mazz. Xu et  al. [53] 
showed that scutellarin markedly inhibited the prolifera-
tion of hepatocellular carcinoma cells in a concentration- 
and time-dependent manner, and it also exhibited the 
reduction of ROS production, STAT3, Bcl-XL and Mcl-1 
protein expression. However, scutellarin is also a drug 
with low water solubility, short half-life, poor bioavail-
ability, and rapid elimination rate from plasma, leading 
to the restriction of its’ application and therapeutic value. 
Frequent oral administration is required to maintain 
drug concentrations within the effective therapeutic win-
dow. A delivery system that can slowly release drugs with 
short half-lives would be good to address the limitations 
of scutellarin. Yang et al. [54] prepared a series of scutel-
larin–cyclodextrin conjugates, in which scutellarin was 
covalently bound to one of the primary hydroxyl groups 
of β-CD. They showed that the aqueous solubility of the 
conjugates was significantly higher than that of scutel-
larin, and the conjugates could hardly be hydrolyzed to 
scutellarin in aqueous solutions. Wei et  al. [55] found 
in comparison to scutellarin, scutellarin-loaded bovine 
serum albumin nanoparticles exhibited a significantly 
higher AUC (2.8-fold). In our experiment, we prepared 
Chit-DC-VB12-Scu and found a significant enhancement 
in the amount of transported scutellarin after incorpo-
ration within VB12-conjugated micelles (4.39 fold), and 
the AUC of scutellarin from the conjugated compounds 
was about two to threefold greater than that from the 
free scutellarin alone. We also found the arrangement of 
ganglion cells and inner nuclear layer cells was disorder 
in the T2D rats’ retina, but after treatment with Chit-DC-
Scu and Chit-DC-VB12-Scu, the structural disorder of 
intraretinal arrangement in the retina was alleviated.
Oral administration of drugs is the most convenient, 
economical, non-invasive route of drug delivery, and has 
the ability to achieve sustained plasma levels of the drug 
[56, 57]. Therefore, attempts to use nanotechnology to 
increase the oral delivery efficacy of classical medicines 
have been promising, and drug release is a key property 
incorporated in the design of such nanoparticles. Caco-
2cells are derived from a human colon tumor. While 
3 weeks cell cultures, Caco-2 cells feature many charac-
teristics of intestinal epithelial cells: a polarized mon-
olayer with tight junctions and microvilli at the apical 
side is formed [58]. Therefore, Caco-2 cells represent a 
widely accepted in  vitro system for the human intesti-
nal metabolism and also for the intestinal absorption of 
organic compounds, and have been recommended by the 
US Food and Drug Administration (FDA) for that pur-
pose [59, 60].
At present, many investigations have indicated that 
polymeric micelles has the capacity of biocompatibility, 
longevity, high stability in  vitro and in  vivo, and it can 
effectively solubilize many poorly soluble pharmaceuti-
cal agents and deliver drugs across physiological barriers 
such as the BBB [61, 62]. Some biodegradable polymers, 
such as chitosan, may enhance the positive charge den-
sity on the nanoparticle surface at a physiological pH, 
thus increase cellular uptake and limit toxicity, which 
may be of use for the oral delivery of drug systems [63]. 
Wang et  al. [61] developed a novel polymeric carrier 
based on chitosan-functionalized Pluronic P123/F68 
micelles loaded with myricetin (MYR-MCs). They found 
MYR-MCs inhibited the growth and proliferation of 
glioblastoma cells, and promoted apoptosis in vitro and 
in  vivo. Additionally, enhanced cellular uptake of myri-
cetin in Caco-2 cells as a result of encapsulation within 
the micelles was achieved. Intrinsic factor (IF), a protein 
produced in the stomach, forms a complex with VB12 
and then binds to IF receptors located in the luminal sur-
face of the intestine and stimulates the internalization of 
VB12. This mechanism has been previously employed to 
deliver drugs through the small intestinal wall. Francis 
et al. [27] reported that oral absorption and delivery effi-
ciency of polymeric micelles were substantially enhanced 
by linkage to VB12 and that the process is initiated by the 
complexation of VB12 with IF. Ke et al. [28] showed that 
VB12 modified nanoparticles significantly improved the 
drug internalization and the transport efficacy through 
cell monolayer. According to these findings, we designed 
and synthesized the Chit-DC-VB12 nanoparticles, while 
the FTIR, 1H NMR and UV–Vis analyses confirmed that 
the deoxycholic acid residues and vitamin B12 residues 
were conjugated with the chitosan chains and their DS 
values were 3 and 0.3%, respectively. Furthermore, we 
found Chit-DC-VB12 nanoparticles exhibited high per-
meation in Caco-2 cell, and it also had a high cellular 
uptake.
Using color Doppler imaging, investigators have 
shown that the initial changes in the retrobulbar circu-
lation occur in the central retinal vein (CRV) during the 
progression of diabetic retinopathy [40, 64]. In previous 
study, diabetic patients have presented with significantly 
lower blood flow velocity in both the CRA and CRV 
than in the corresponding vessels of normal eyes, and 
this reduction in velocity may arise from an increase in 
the resistance induced by diabetic retinal microvascular 
obstructions [65]. In our study, we choose type II diabetic 
rats as a model to investigate the antiangiogenic activity 
and vascular effect of scutellarin-loaded nanoparticles. 
In accordance with the results reported previously, we 
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found that the blood flow velocities in diabetic rats were 
significantly lower, and the resistivity indexes were signif-
icantly higher than that of non-diabetic rats (Fig. 7). Our 
results indicate that treatment with scutellarin by itself 
can reduce the retinal resistivity index value and increase 
the blood flow velocity in the retinas of diabetic rats; it is 
much more effective when administered as Chit-DC-Scu 
and Chit-DC-VB12-Scu.
Conclusion
We have developed Chit-DC and Chit-DC-VB12 through 
a self-assembly mechanism. Chit-DC is low toxicity and 
Chit-DC-VB12 displayed a greater capacity to trans-
port across Caco-2 compared to Chit-DC. Pathological 
analysis and blood flow velocities of the retinas showed 
that scutellarin therapy attenuated the retinal damage of 
diabetic rats, and that treatment with Chit-DC-Scu and 
Chit-DC-VB12-Scu was more effective than the scutel-
larin alone. Scutellarin downregulated the expression of 
VEGF, VEGFR2 and vWF in the retina of diabetic rats 
and the nano materials in our study increase the efficacy 
of scutellarin. Our results indicate that Chit-DC-VB12, as 
a promising vector of drugs, increased the bioavailability 
of scutellarin. Therefore, Chit-DC-VB12-Scu has poten-
tial therapeutic applications for the treatment of diabetic 
retinopathy.
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